Aethlon Medical to Publish Long COVID Study on November 20, 2025
Aethlon Medical announced the 20 November 2025 publication of a pre-clinical study in the pre-print online archive bioRxiv, simultaneously been submitted for consideration to a peer-reviewed journal. Long COVID refers to persistent symptoms following acute COVID-19 infection. These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain, and cognitive difficulties such as "brain fog" - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the U.S. alone with symptoms lasting a year. No treatment has proven effective. Extracellular vesicles, or EVs, nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID. Aethlon Medical's Hemopurifier is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin, or GNA, previously found to bind to the sugar mannose. The Hemopurifier has previously been shown to remove EVs and decrease microRNAs in a patient with severe acute COVID-19 infection. Plasma of those with Long COVID contained elevated levels of both large and small EVs. Removal of small EVs by the GNA affinity resin correlated with mannose positive large EVs indicating the same glycan target for removal by the Hemopurifier was present in both populations.
Trade with 70% Backtested Accuracy
Analyst Views on AEMD
About AEMD
About the author
Aethlon Medical Schedules Q3 Financial Results Conference Call
- Financial Results Announcement: Aethlon Medical will release its fiscal third-quarter financial results for the period ending December 31, 2025, on February 12, 2026, at 4:15 p.m. ET, highlighting advancements in cancer and life-threatening infectious disease treatments.
- Conference Call Details: Management will host a conference call on the same day at 4:30 p.m. ET to review financial results and recent corporate developments, followed by a Q&A session to enhance interaction between investors and management.
- Registration Process: Interested parties can register via a provided link to receive dial-in numbers, while those unable to pre-register can call the toll-free number 1-844-836-8741 or the international number 1-412-317-5442 to ensure participation in the call.
- Hemopurifier Device Overview: Aethlon's Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections, having received FDA Breakthrough Device designation, demonstrating potential in treating patients with refractory cancer.
Aethlon Medical Secures $3.3 Million Financing to Accelerate Cancer Treatment
- Financing Agreement: Aethlon Medical has entered into a securities purchase agreement with a single institutional investor to sell 595,897 shares and warrants for 1,042,820 shares, raising approximately $3.3 million, expected to close on December 8, 2025, enhancing liquidity for R&D support.
- Warrant Inducement: The company has negotiated a warrant inducement agreement to lower the exercise price of March and September 2025 warrants to $4.03, which is expected to encourage the investor to exercise these warrants, providing additional funding for the company.
- Market Compliance: This financing adheres to Nasdaq rules under Section 4(a)(2) of the Securities Act, ensuring the company's compliance in capital markets, which enhances investor confidence and improves the company's reputation.
- Future Growth Potential: Aethlon is focused on developing the Hemopurifier to address unmet needs in oncology and infectious diseases, and this financing will accelerate clinical trial processes, boosting the company's competitiveness in the medical device sector.
American Eagle Shares Rise 15%; Check Out 20 Stocks Making Moves in Premarket Trading
American Eagle Outfitters Performance: American Eagle Outfitters Inc. reported third-quarter revenue of $1.36 billion and adjusted earnings of 53 cents per share, both exceeding analyst expectations, leading to a 14.8% increase in share price during pre-market trading.
Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including Powell Max Ltd (up 70%), Creative Media & Community Trust Corp (up 53.3%), and SMX (up 27.3%).
Significant Losers: Lulu’s Fashion Lounge Holdings Inc. experienced a dramatic drop of 58.3%, while ScanTech AI Systems Inc. fell 35.8% after receiving a delisting determination from Nasdaq.
Market Reactions: The overall market showed mixed reactions with various companies reporting earnings and guidance updates, impacting their stock prices significantly in pre-market trading.
Aethlon Medical Publishes Long COVID Study Findings
- Research Advancement: Aethlon Medical's preclinical study published on November 20, 2025, indicates that elevated extracellular vesicles in Long COVID plasma may provide a therapeutic target for Galanthus nivalis agglutinin (GNA) affinity resin, suggesting potential breakthroughs in Long COVID treatment.
- Clinical Collaboration: The study, conducted in partnership with the UCSF Long COVID clinic, analyzed plasma samples from Long COVID patients and recovered controls, revealing significantly higher levels of extracellular vesicles in Long COVID patients, highlighting the device's potential application in treating post-COVID symptoms.
- Technological Innovation: The Hemopurifier® device effectively removes harmful extracellular vesicles through plasma separation and GNA affinity resin, previously demonstrated in severe acute COVID-19 patients, indicating its potential efficacy in Long COVID patients and expanding its clinical application scope.
- Market Potential: With Long COVID affecting 44 to 48 million people in the U.S. and an estimated economic burden of $2 billion, Aethlon's research findings could introduce new treatment options in this area, enhancing the company's competitiveness in the medical device market.
Aethlon Medical Publishes Long COVID Study Results
- Research Advancement: Aethlon Medical's preclinical study published on November 20, 2025, reveals significantly increased extracellular vesicles in Long COVID plasma, providing a potential therapeutic target for Galanthus nivalis agglutinin affinity resin, paving the way for new treatment developments.
- Economic Impact: With Long COVID affecting 44 to 48 million people in the U.S. and a projected economic burden of $2 billion, Aethlon's research offers new hope for addressing this major public health issue, potentially attracting more research funding.
- Technological Innovation: The Hemopurifier® device effectively removes harmful extracellular vesicles through plasma separation and specific affinity resin, demonstrating potential in Long COVID treatment and possibly altering existing therapeutic strategies.
- Clinical Collaboration: Aethlon's collaboration with the UCSF Long COVID clinic to analyze patient plasma samples indicates the device's effectiveness in removing microRNAs associated with inflammation, potentially supporting future clinical trials.
Aethlon Medical Reports Financial Results and Corporate Update for Fiscal Q2 2025
Financial Performance: Aethlon Medical reported a 48% reduction in operating expenses for the fiscal second quarter ended September 30, 2025, resulting in an operating loss of $1.5 million, down from $2.8 million in the previous year.
Clinical Progress: Recruitment for the second cohort of the Australian oncology trial using the Hemopurifier has begun, focusing on patients with solid tumors who have not responded to PD-1 therapy, with initial results showing potential decreases in extracellular vesicle concentrations.
Scientific Collaboration: The company is collaborating with UCSF on Long COVID research, analyzing extracellular vesicle cargo from patient samples, and preparing a manuscript for peer review.
Operational Updates: Aethlon has resolved compliance issues with Nasdaq, maintaining its listing, and is exploring the compatibility of the Hemopurifier with a simplified blood treatment system for future oncology applications.
Aethlon Medical Schedules Q3 Financial Results Conference Call
- Financial Results Announcement: Aethlon Medical will release its fiscal third-quarter financial results for the period ending December 31, 2025, on February 12, 2026, at 4:15 p.m. ET, highlighting advancements in cancer and life-threatening infectious disease treatments.
- Conference Call Details: Management will host a conference call on the same day at 4:30 p.m. ET to review financial results and recent corporate developments, followed by a Q&A session to enhance interaction between investors and management.
- Registration Process: Interested parties can register via a provided link to receive dial-in numbers, while those unable to pre-register can call the toll-free number 1-844-836-8741 or the international number 1-412-317-5442 to ensure participation in the call.
- Hemopurifier Device Overview: Aethlon's Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections, having received FDA Breakthrough Device designation, demonstrating potential in treating patients with refractory cancer.
Aethlon Medical Secures $3.3 Million Financing to Accelerate Cancer Treatment
- Financing Agreement: Aethlon Medical has entered into a securities purchase agreement with a single institutional investor to sell 595,897 shares and warrants for 1,042,820 shares, raising approximately $3.3 million, expected to close on December 8, 2025, enhancing liquidity for R&D support.
- Warrant Inducement: The company has negotiated a warrant inducement agreement to lower the exercise price of March and September 2025 warrants to $4.03, which is expected to encourage the investor to exercise these warrants, providing additional funding for the company.
- Market Compliance: This financing adheres to Nasdaq rules under Section 4(a)(2) of the Securities Act, ensuring the company's compliance in capital markets, which enhances investor confidence and improves the company's reputation.
- Future Growth Potential: Aethlon is focused on developing the Hemopurifier to address unmet needs in oncology and infectious diseases, and this financing will accelerate clinical trial processes, boosting the company's competitiveness in the medical device sector.
American Eagle Shares Rise 15%; Check Out 20 Stocks Making Moves in Premarket Trading
American Eagle Outfitters Performance: American Eagle Outfitters Inc. reported third-quarter revenue of $1.36 billion and adjusted earnings of 53 cents per share, both exceeding analyst expectations, leading to a 14.8% increase in share price during pre-market trading.
Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including Powell Max Ltd (up 70%), Creative Media & Community Trust Corp (up 53.3%), and SMX (up 27.3%).
Significant Losers: Lulu’s Fashion Lounge Holdings Inc. experienced a dramatic drop of 58.3%, while ScanTech AI Systems Inc. fell 35.8% after receiving a delisting determination from Nasdaq.
Market Reactions: The overall market showed mixed reactions with various companies reporting earnings and guidance updates, impacting their stock prices significantly in pre-market trading.
Aethlon Medical Publishes Long COVID Study Findings
- Research Advancement: Aethlon Medical's preclinical study published on November 20, 2025, indicates that elevated extracellular vesicles in Long COVID plasma may provide a therapeutic target for Galanthus nivalis agglutinin (GNA) affinity resin, suggesting potential breakthroughs in Long COVID treatment.
- Clinical Collaboration: The study, conducted in partnership with the UCSF Long COVID clinic, analyzed plasma samples from Long COVID patients and recovered controls, revealing significantly higher levels of extracellular vesicles in Long COVID patients, highlighting the device's potential application in treating post-COVID symptoms.
- Technological Innovation: The Hemopurifier® device effectively removes harmful extracellular vesicles through plasma separation and GNA affinity resin, previously demonstrated in severe acute COVID-19 patients, indicating its potential efficacy in Long COVID patients and expanding its clinical application scope.
- Market Potential: With Long COVID affecting 44 to 48 million people in the U.S. and an estimated economic burden of $2 billion, Aethlon's research findings could introduce new treatment options in this area, enhancing the company's competitiveness in the medical device market.
Aethlon Medical Publishes Long COVID Study Results
- Research Advancement: Aethlon Medical's preclinical study published on November 20, 2025, reveals significantly increased extracellular vesicles in Long COVID plasma, providing a potential therapeutic target for Galanthus nivalis agglutinin affinity resin, paving the way for new treatment developments.
- Economic Impact: With Long COVID affecting 44 to 48 million people in the U.S. and a projected economic burden of $2 billion, Aethlon's research offers new hope for addressing this major public health issue, potentially attracting more research funding.
- Technological Innovation: The Hemopurifier® device effectively removes harmful extracellular vesicles through plasma separation and specific affinity resin, demonstrating potential in Long COVID treatment and possibly altering existing therapeutic strategies.
- Clinical Collaboration: Aethlon's collaboration with the UCSF Long COVID clinic to analyze patient plasma samples indicates the device's effectiveness in removing microRNAs associated with inflammation, potentially supporting future clinical trials.
Aethlon Medical Reports Financial Results and Corporate Update for Fiscal Q2 2025
Financial Performance: Aethlon Medical reported a 48% reduction in operating expenses for the fiscal second quarter ended September 30, 2025, resulting in an operating loss of $1.5 million, down from $2.8 million in the previous year.
Clinical Progress: Recruitment for the second cohort of the Australian oncology trial using the Hemopurifier has begun, focusing on patients with solid tumors who have not responded to PD-1 therapy, with initial results showing potential decreases in extracellular vesicle concentrations.
Scientific Collaboration: The company is collaborating with UCSF on Long COVID research, analyzing extracellular vesicle cargo from patient samples, and preparing a manuscript for peer review.
Operational Updates: Aethlon has resolved compliance issues with Nasdaq, maintaining its listing, and is exploring the compatibility of the Hemopurifier with a simplified blood treatment system for future oncology applications.
